Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2022

Are novel immunotherapeutics and targeted treatments going to transform the management of CRC? 

Drugging KRAS in CRC: where do we stand?

Date

09 Sep 2022

Session

Are novel immunotherapeutics and targeted treatments going to transform the management of CRC? 

Topics

Translational Research;  Therapy

Tumour Site

Colon and Rectal Cancer

Presenters

Rodrigo Dienstmann

Authors

R. Dienstmann

Author affiliations

  • Oncology Data Science Department, Grupo Oncoclinicas, 04543-906 - Sao Paulo/BR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Introduction and scientific background

Presenter: Clara Montagut Viladot

Session: Are novel immunotherapeutics and targeted treatments going to transform the management of CRC? 

Resources:

Slides

Webcast

Targeting the uncommon molecular alterations

Presenter: Andrea Sartore Bianchi

Session: Are novel immunotherapeutics and targeted treatments going to transform the management of CRC? 

Resources:

Slides

Webcast

Conclusions and perspectives 

Presenter: Andrea Sartore Bianchi

Session: Are novel immunotherapeutics and targeted treatments going to transform the management of CRC? 

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.